Utility values for chronic myelogenous leukemia chronic phase health states from the general public in the United Kingdom

Abstract

This study estimated time trade-off preference values associated with the four chronic myelogenous leukemia (CML) chronic phase-related health states (i.e. untreated, hematologic response, cytogenetic response and molecular response) among members of the general public in the UK (n = 241). All four health states were associated with decreases in preference values from full health. The molecular response to treatment was the most preferred health state (mean utility of 0.94). The second-most preferred health state was cytogenetic response followed by hematologic response (mean utilities were 0.89 and 0.80, respectively). The least preferred health state was untreated chronic phase CML (mean utility of 0.72). The utility values for each state were significantly different from one another (p < 0.001). This study demonstrated and quantified the impact that more robust treatment responses have on the health-related quality of life of patients with chronic phase CML.

Keywords::

• Chronic myelogenous leukemia
• utility
• time trade-off
• UK, standard gamble

Acknowledgements

This study was funded by Novartis Pharmaceuticals, East Hanover, NJ, USA, manufacturers of imatinib mesylate (Glivec) and nilotinib (Tasigna).

Potential conflict of interest:

Disclosure forms provided by the authors are available with the full text of this article at www.informahealthcare.com/lal.